We identify here the GSTP1 and FOXC1 methylation status as independent prognostic markers for breast cancer survival in a uniform patient cohort receiving neoadjuvant doxorubicin monotherapy prior to surgery and five years of tamoxifen for all ER positive patients according to a clinical study protocol [24]. Here, ESR1 is linked to breast cancer.